Ipilimumab: Indications and Clinical Management

Shailender Bhatia, MD December, 2013






Fred Hutchinson Cancer Research Center UW Medicine Seattle Children's




Presentation Outline

- Mechanism of action (CTLA-4)
- Clinical Indication(s) for using Ipilimumab
- Efficacy and response characteristics in melanoma
- Adverse events (AEs) and management
- Patient selection/sequencing of therapies in melanoma
- Future Directions

Ipilimumab: Mechanism of Action



Precise mechanisms of efficacy of anti-CTLA4-ab in humans are still unclear



 Clinical responses are accompanied by increased infiltration of CD8 T-cells in melanoma tumors.

[Ribas A et al. Clin Ca Res. 2009]

Presentation Outline

- Mechanism of action (CTLA-4)
- Clinical Indication(s) for using Ipilimumab
- Efficacy and response characteristics in melanoma
- Adverse events (AEs) and management
- Patient selection/sequencing of therapies in melanoma
- Future Directions

Indication for Ipilimumab (YervoyTM)

Yervoy TM was approved by the US FDA in **2011** for "the treatment of <u>unresectable</u> or <u>advanced</u> **melanoma**"

Approved dose is **3 mg/kg** administered IV over 90 minutes every 3 weeks for a total of 4 doses.

Until recently, few standard therapy options existed for advanced melanoma.

US-FDA approved therapies for metastatic melanoma.

Treatment of Metastatic Melanoma: An Overview Bhatia S et al. <u>ONCOLOGY</u>. 2009; 23:6; 488-500

2010: The ceiling was finally broken

ORIGINAL ARTICLE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, M.D., Steven J. O'Day, M.D., David F. McDermott, M.D.,

[Hodi FS et al. <u>NEJM</u>. 2010]

Presentation Outline

- Mechanism of action (CTLA-4)
- Clinical Indication(s) for using Ipilimumab
- Efficacy and response characteristics in melanoma
- Adverse events (AEs) and management
- Patient selection/sequencing of therapies in melanoma
- Future Directions


Trial Design and Patient demographics

- N = 676 melanoma patients
- 3:1:1 randomization to Ipi plus gp100, Ipi alone and gp100 alone respectively

- Pre-treated patient population (23% with prior IL-2)
- 7**3% M1c**; elevated LDH (38%)
- ECOG 0 (53%) or 1 (47%)

Hodi FS et al. <u>NEJM</u>. 2010

Improved Overall Survival was seen in both the Ipilimumab arms (<u>3mg/kg q3 wks x4</u>)



Hodi FS et al. NEJM. 2010

However, objective responses are infrequent, and complete remissions rare.

Response and Time to Event	Ipilimumab plus gp100 (N=403)	Ipilimumab Alone (N=137)	gp100 Alone (N=136)
Induction			
Best overall response — no. (%)			
Complete response	1 (0.2)	2 (1.5)	0
Partial response	22 (5.5)	13 (9.5)	2 (1.5)
Stable disease	58 (14.4)	24 (17.5)	13 (9.6)
Progressive disease	239 (59.3)	70 (51.1)	89 (65.4)
Not evaluated	83 (20.6)	28 (20.4)	32 (23.5)
Best overall response rate — % (95% CI)	5.7 (3.7-8.4)	10.9 (6.3–17.4)	1.5 (0.2-5.2)
P value for comparison with gp100 alone	0.04	0.001	
P value for comparison with ipilimumab alone	0.04	—	
Disease control rate — % (95% CI)†	20.1 (16.3–24.3)	28.5 (21.1-36.8)	11.0 (6.3–17.5)
P value for comparison with gp100 alone	0.02	<0.001	
P value for comparison with ipilimumab alone	0.04	—	
Time to event — mo			
Time to progression — median (95% CI)	2.76 (2.73-2.79)	2.86 (2.76–3.02)	2.76 (2.73-2.83)
Time to response — mean (95% CI)	3.32 (2.91-3.74)	3.18 (2.75-3.60)	2.74 (2.12-3.37)
Duration of response — median (95% CI)	11.5 (5.4–NR)	NR (28.1–NR)	NR (2.0–NR)

Responses are usually delayed (12-16 weeks), but tend to be durable.

Response and Time to Event	Ipilimumab plus gp100 (N=403)	lpilimumab Alone (N=137)	gp100 Alone (N=136)
Induction			
Best overall response — no. (%)			
Complete response	1 (0.2)	2 (1.5)	0
Partial response	22 (5.5)	13 (9.5)	2 (1.5)
Stable disease	58 (14.4)	24 (17.5)	13 (9.6)
Progressive disease	239 (59.3)	70 (51.1)	89 (65.4)
Not evaluated	83 (20.6)	28 (20.4)	32 (23.5)
Best overall response rate — % (95% CI)	5.7 (3.7-8.4)	10.9 (6.3–17.4)	1.5 (0.2-5.2)
P value for comparison with gp100 alone	0.04	0.001	
P value for comparison with ipilimumab alone	0.04	—	
Disease control rate — % (95% CI)†	20.1 (16.3-24.3)	28.5 (21.1-36.8)	11.0 (6.3–17.5)
P value for comparison with gp100 alone	0.02	<0.001	
P value for comparison with ipilimumab alone	0.04	—	
Time to event — mo			
Time to progression — median (95% CI)	2.76 (2.73–2.79)	2.86 (2.76–3.02)	2.76 (2.73-2.83)
Time to response — mean (95% CI)	3.32 (2.91-3.74)	3.18 (2.75–3.60)	2.74 (2.12-3.37)
Duration of response — median (95% CI)	11.5 (5.4-NR)	NR (28.1–NR)	NR (2.0-NR)

Ipilimumab: Delayed Onset of Responses



Week 16: continued improvement

Week 12: swelling & progression



Week 72: complete remission

Week 14: improved

Week 108: complete remission







Acquired resistance to Ipilimumab after having an initial response may be overcome by <u>Reinduction</u> dosing

Reinduction‡			
Best overall response — no./total no. (%)			
Complete response	0	1/8 (12.5)	0
Partial response	3/23 (13.0)	2/8 (25.0)	0
Stable disease	12/23 (52.2)	3/8 (37.5)	0
Progressive disease	8/23 (34.8)	2/8 (25.0)	1/1 (100.0)

Hodi FS et al. <u>NEJM</u>. 2010

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

> Dacarbazine <u>850</u> mg/m2 q 3 weeks x 8 doses + Ipilimumab (or placebo) 10 mg/kg q 3 weeks x 4 (Induction), then q 12 wk (Maintenance)

> > [Robert C et al. <u>NEJM</u>. 2011]

Improved OS in the Ipilimumab+DTIC arm

A



No. at Risk Ipilimumab-dacarbazine	250	230	199	181	157	131	11	4 1	04 91	85	79	74	68	61	5	9 50	5 56		ard	8	17	10 wit	4 h	2	0
End Point									imu Dacal (N=		ne	5		Daca	art	o pli pazir 252)	1e		ilimu Daca (95	arb		ne	S	P	Value
Primary end point: ove	rall s	urvi	val																						
No. of deaths									1	96					21	8		0.	72 (0).59	9-0	.87)	<	0.001
Survival — % (95% CI)	l Ip	oi n	no	no) 3r	ng	/k	a																	
1 yr	-1-			45		3		U	3 (4)	1.0-5	53.6)		36	.3 (3	30.	4-4	2.4)								
2 yr				24	%			28.	5 (22	2.9-3	34.2)		17	.9 (1	13.	3-2	2.8)								
3 yr								20.	8 (1	5.7-2	26.1)		12	2.2 (8.2	2-16	5.5)								

[Robert C et al. <u>NEJM</u>. 2011]

Optimal dose and schedule still need to be determined

	Ipi 3 mg/kg alone Re-induction allowed (n=137)	Ipi 10mg/kg + DTIC with maintenance (n=250)
Baseline characteristics	M1c - 73% ECOG 1 - 47% Elevated LDH - 38% Pretreated	M1c - 69% ECOG 1 - 48% Elevated LDH - 49% Treatment-naive
Median OS (mos)	10.1	11.2
1 yr-OS	45%	47%
2 yr-OS	24%	28%
Best ORR	11%	15%
Grade 3-4 IRAE	15%	41%
Cost (Induction only) {assuming 60kg person)	~\$120,000	\$400,000
References	Hodi <u>NEJM</u> 2010	Robert <u>NEJM</u> 2011

While CR rate is low, there is a potential for long-term survival in a subset of patients

• Retrospective analysis of 1861 patients treated with Ipilimumab on several clinical trials.

➢OS curve begins to plateau at around 3 years and extends up to 10 years.

➢OS at 3 years was 21% and at 5 years was 18%

[Hodi FS et al. 2013 ESMO (abstract # LBA24)]

Presentation Outline

- Mechanism of action (CTLA-4)
- Clinical Indication(s) for using Ipilimumab
- Efficacy and response characteristics in melanoma
- Adverse events (AEs) and management
- Patient selection/sequencing of therapies in melanoma
- Future Directions

Adverse Events from Ipilimumab

Immune-related AE	Any grade (%)	Grade 3 or higher (%)
Any IrAE	60	15
Dermatologic (pruritis, rash, vitiligo)	43	2
GI (Diarrhea, colitis)	29	8
Endocrine (Hypohysitis, hypothyroidism, adrenal insuff)	8	2
Hepatic	4	0
Others	5	2
		2010]

[Hodi FS et al. <u>NEJM</u>. 2010]

Adverse Events (contd.)

 Toxicities are manageable and usually reversible with immunosuppression, when <u>identified and treated</u> <u>promptly</u>.

Type of Immune-Related Adverse Event	Median Time to Onset, wk	Median Time From Onset to Resolution, wk
Skin	3	5
Hepatic	3-9	0.7-2.0
Gastrointestinal reactions	8	4
Endocrine	7-20	NR

[Weber JS et al. Cancer. 2013]

Unusual (immune-mediated) AEs have also been reported, but are infrequent.

Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for Melanoma A Case Report

Shailender Bhatia,* Bertrand R. Huber,† Melissa P. Upton,† and John A. Thompson*

[Bhatia S et al. JIT. 2009]

 Neuropathy, meningitis, interstitial nephritis, pneumonitis, sarcoidosis, eosinophilia, pericarditis, pancreatitis, episcleritis/uveitis *et cetera* have been reported.

Presentation Outline

- Mechanism of action (CTLA-4)
- Clinical Indication(s) for using Ipilimumab
- Efficacy and response characteristics in melanoma
- Adverse events (AEs) and management
- Patient selection/sequencing of therapies in melanoma
- Future Directions

How to choose amongst therapeutic options?

- 1. Establish goals of care
 - Durable disease-control
 - Rapid symptom palliation
 - Quality-of-life
- 2. Match desired goals to the safety/efficacy characteristics of the therapy
 - Rate of tumor regression (ORR) or clinical benefit
 - Kinetics of response (rapid vs delayed)
 - Duration of response
 - AEs
 - ?Cost

How to choose amongst therapeutic options?: The <u>SB</u> approach

	BRAF wild type	BRAF mutated
Low Volume, Asymptomatic disease	Immunotherapy (HD IL-2 or Ipilimumab or other)	Immunotherapy (preferred) Vemurafenib (fine)
Bulky disease, Symptomatic	Chemotherapy Ipilimumab (if life expectancy >12 weeks	Vemurafenib followed by immunotherapy

Presentation Outline

- Mechanism of action (CTLA-4)
- Clinical Indication(s) for using Ipilimumab
- Efficacy and response characteristics in melanoma
- Adverse events (AEs) and management
- Patient selection/sequencing of therapies in melanoma
- Future Directions

True impact of Ipilimumab's success story goes far beyond Melanoma

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JUNE 28, 2012

VOL. 366 NO. 26

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

[Topalian S et al. <u>NEJM</u>. 2013; Brahmer J et al. <u>NEJM</u>. 2013]

The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, M.D., Ph.D., Harriet Kluger, M.D., Margaret K. Callahan, M.D., Ph.D., Michael A. Postow, M.D., Naiyer A. Rizvi, M.D., Alexander M. Lesokhin, M.D., Neil H. Segal, M.D., Ph.D., Charlotte E. Ariyan, M.D., Ph.D., Ruth-Ann Gordon, B.S.N., Kathleen Reed, M.S., Matthew M. Burke, M.B.A., M.S.N., Anne Caldwell, B.S.N., Stephanie A. Kronenberg, B.A., Blessing U. Agunwamba, B.A., Xiaoling Zhang, Ph.D., Israel Lowy, M.D., Ph.D., Hector David Inzunza, M.D., William Feely, M.S., Christine E. Horak, Ph.D., Quan Hong, Ph.D., Alan J. Korman, Ph.D., Jon M. Wigginton, M.D., Ashok Gupta, M.D., Ph.D., and Mario Sznol, M.D.


[Wolchok J et al. <u>NEJM</u>. 2013]

Near-CRs seen in a large proportion of pts



[Wolchok J et al. NEJM. 2013]

Tumor regression occurs faster and much more frequently than Ipilimumab



Nivo (1 mg/kg) and Ipi (3 mg/kg)


[Wolchok J et al. NEJM. 2013]

Safety Observations

- Toxicities reported to be manageable and reversible with immunosuppression.
- Grade 3/4 treatment-related AEs: 53%
- Elevations in Lipase (13%), AST (13%, ALT (11%)
- Cohort 3 (Nivo 3 + Ipi 3) deemed to have unacceptable level of toxicity
- 3/6 patients had Gr 3 or 4 lipase elevations lasting more than 3 weeks.

[Wolchok J et al. <u>NEJM</u>. 2013]

Why does immunotherapy <u>not</u> work all the time?



[Weiner L NEJM 2008]

Until CURE happens, participation in welldesigned clinical trials should be considered Standard of Care

	Therapeutic Trials at SCCA (not including the T-cell Therapy trials)							
Disease Status	Immunotherapy	Targeted therapy						
1 st Line Metastatic	lpi+PD1 vs lpi vs PD1	BRAFi+Bevacizumab						
	lpi vs PD1							
	PD-1 versus Chemo							
2 nd Line or NOS	IL-12 Electroporation (M1a)	Several planned						
	IL-21+Ipilimumab/PD1							
	PD1 Biomarker							

Questions